Forecasting and intelligence while the asset is still in development.
- Market Sizing (Epi-based)
- Stage-Gate Assessments
- Asset Valuation Models
- BD&L support
- Pipeline & Portfolio Monitoring
Since 2018 · Gurugram · Boston · Zug
PharmSight blends technology, business, and therapy-area expertise to improve commercial performance and give teams a clear view of the market.
Why teams choose us
Technology, business, and pharma on one team, so findings turn into action.
Oncology, neurology, immunology, and a wide range of other markets.
A single project, a retained partner, or an analyst team embedded with yours.
Cintel, Conversity, IntelliSight, and PharmLens keep working after the project.
Hubs in Gurugram, Boston, and Zug, working across time zones.
End-to-end, across the lifecycle
Forecasting and intelligence while the asset is still in development.
Evidence, landscape, and forecasts brought together for a launch plan.
Analytics that keep an in-line brand growing and its access protected.
AI tool · Service Finder
Search by keyword, or filter by practice. Results update as you type.
28 services
No services match. Try a shorter word, or choose “All”.
AI tool · Brief Builder
Answer three questions and the builder drafts a short brief you can share with PharmSight. The text is assembled from templates on this page — it is not a live AI model and nothing is sent.
Featured products

News, events, congress coverage, analyst commentary, and historical sales in one place.

AI-powered negotiation and sales training for pricing and objection handling.

A conversational interface that lets business users question their data directly.
Part of the proprietary toolkit. A public product screen has not been released yet.
News
Europe
PharmSight GmbH opens in Zug, with Conversity part of the launch.
United States
A US subsidiary closer to American brand and access teams.
Products
Cintel, Conversity, IntelliSight, and PharmLens now sit together.
Join us
Contact
This form stays in your browser — nothing is sent.